Gliptins (DPP-4 inhibitors) (Oral Hypoglycemics)

Question 1

Gliptins (DPP-4 inhibitors)

Answer 1

Sitagliptin (Januvia)
Saxagliptin (Onglyza)
Linagliptin (Tradjenta)

Question 2

Therapeutic Uses
Sitagliptin (Januvia)
Saxagliptin (Onglyza)
Linagliptin (Tradjenta)

Answer 2

Type 2 diabetes

Question 3

Mechanism of Action
Sitagliptin (Januvia)
Saxagliptin (Onglyza)
Linagliptin (Tradjenta)

Answer 3

Inhibits peptidyl peptidase, blocking breakdown of incretin hormones such as glucagon-like peptide-1 (GLP-1). Normally GLP-1 stimulates insulin release from the pancreas and inhibits the liver’s production of glucose, therefore by inhibiting the breakdown of GLP-1 increases GLP-1 levels resulting in increased insulin release and reduced production of glucose by the liver.

Question 4

Adverse Effects
Sitagliptin (Januvia)
Saxagliptin (Onglyza)
Linagliptin (Tradjenta)

Answer 4

mild stomach discomfort, diarrhea

Question 5

Administration
Sitagliptin (Januvia)
Saxagliptin (Onglyza)
Linagliptin (Tradjenta)

Answer 5

Taken orally once daily